Stocktaking: Lancet Research Selection sq., May 23, 2020

1Evaluation of the effectiveness of the early breast cancer program at 26Gy 1 week after surgery
DOI: https://doi.org/1016/S0140-6736 (20) 30932-6recently published the results of the 5-year fast-forward trial by researchers, which examined the effects of the 5-0-per-breast screening program in early breast cancer patientsbreast-immersion cancer patients over the age of 18 years of age (pT1-3, pN0-1, M0) underwent breast-care surgery or mastectomy, randomly divided into more than 3 weeks, a total of 15 times, a total of 40 Gy radiotherapy, 1 week or more, a total of 27 Gy radiation or more than 1 week, a total of 5 times, a total of 26 GyThe main endpoint of the study was the recurrence of the same-sided breast tumor4,096 patients participated, of whom 1,361 received 40Gy treatment, 1,367 patients received 27Gy treatment and 1,368 patients received 26Gy treatmentIn the median follow-up of 71.5 months, 79 patients (31 in the 40 Gy group, 27 in the 27 Gy group, 21 in the 26 Gy group) had major endpoint events, with a recurrence risk of 0.86 compared to the 27 Gy group in the 40 Gy group and 0.67 compared to the 26 Gy groupThe absolute differences in risk in the 27Gy and 26 Gy groups were -0.3% and -0.7%, respectively, compared to the 40 Gy groupOver the course of 5 years, 98 (9.9%) patients in the 40Gy group, 155 patients in the 27Gy group (15.4%) and 121 (11.9%) in the 26Gy group had normal tissue effects in breast or chest wall evaluationIn the evaluation of clinicians, the clinical advantage ratio for the 27Gy group was 1.55 and the 26Gy group was 1.12 compared to the 40Gy groupPatient and photographic assessments showed that 27 Gy had a higher risk of impact on normal tissue than 40 Gy, but a lower risk of normal tissue impact in the 26 Gy groupcell therapy is used for the prevention andof acute rejection after kidney transplantation
DOI:https://doi.org/10.1016/S0140-6736 (20) 30167-7 Cell Drug Therapy (Cbmps) is one of the most advanced ways to reduce immune rejection in organ transplants, and researchers recently examined the safety of using a variety of regulatory Cbmps therapy in kidney transplants ONE Study was conducted in Europe and the United States, followed by patients aged 18 and over who received live kidney transplants for 60 weeks, and the control group received standard post-transplant care, including ballyxizumab, steroids, mycophenolicacids and tamoxet, the study group received CBMPs treatment, CBMP program included 6 types, patients receiving CBMP maintenance therapy after immunosuppressive therapy induction The main endpoint of the study was a biopsy within 60 weeks confirming acute rejection (BCAR) 130 patients participated in the study, of whom 104 completed, 66 received standard care and 38 received CBMP treatment The rate of BCAR after treatment was 12% in the standard treatment group, compared with 16% in the CBMP treatment group Fifteen patients treated with CBMP (40%) did not receive mycophenolic acid treatment, only tamcmos mono-drug maintenance therapy BCAR treatment is safe and has fewer infections 3, 2000-2017 India's Child and Newborn Death Burden Study DOI: https://doi.org/10.1016/S0140-6736 (20) 30471-2
India has made significant progress in improving child survival over the past few decades, in recent days The researchers looked at five-year mortality (U5MR) and neonatal mortality (NMR) for children in India in the 2000-17 range, dividing 31 states and the Federation into three groups based on the Social Population Index (SDI) India's U5MR per 1000 live births fell from 83.1 in 2000 to 42.4 in 2017, and NMR fell from 38.0 to 23.5 in 2017, but in low SDI areas, in 2017, 275 (88%) of the 1,000 live births of U50 00 or more children were above 40, and 291 (93 per cent) and more than 20.2 0 0 0 In 2010-17, the largest decline in Local U5MR was 9.02%, and the largest decline in NMR was 8.05%, with the most significant improvement in Odisha and Assam areas with low SDI, and if this trend continued, India would meet the SDG 2030 U5MR target, but failed to meet the SDG 2030 NMR and NHP 2025 targets Between 2000-17, India saw the highest decline in childhood infectious diseases, a moderate decline in neonatal diseases and the smallest decline in congenital birth defects Child and maternal malnutrition are the main risk factors, resulting in 68.2 per cent of deaths among children under 5 years of age and 83.0 per cent of neonatal deaths in India in 2017, 10.8 per cent of deaths of children under 5 years of age attributable to unsafe water and sanitation and 8.8 per cent to air pollution Source: MedSci Original